Core Viewpoint - Mengke Pharmaceutical is an innovative pharmaceutical company focused on the research and development of anti-infective drugs, with global independent intellectual property rights and international competitiveness [1] Financial Performance - For Q3 2025, Mengke Pharmaceutical reported revenue of 104 million, ranking 104th among 110 companies in the industry, significantly lower than the top company, East China Pharmaceutical, which had 32.664 billion [2] - The net profit for the same period was -194 million, also ranking 104th, with the industry leader, Heng Rui Pharmaceutical, achieving a net profit of 5.76 billion [2] Financial Ratios - As of Q3 2025, Mengke Pharmaceutical's debt-to-asset ratio was 64.57%, higher than the previous year's 41.52% and above the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 84.88%, an increase from 82.23% year-on-year, and higher than the industry average of 57.17% [3] Management Compensation - The chairman and general manager, Zhengyu Yuan, received a salary of 3.764 million in 2024, a decrease of 79,100 from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 14.18% to 16,500, with an average holding of 31,900 circulating A-shares, up 25.73% [5] - Mengke Pharmaceutical plans to raise no more than 1.033 billion through a private placement to Nanjing Haiqing Pharmaceutical, which will become the controlling shareholder, potentially enhancing the company's resource capabilities [5] - The funds raised will accelerate overseas clinical research for anti-infective drugs MRX-5 and MRX-8, and the core product, Contizole tablets, is now available in 580 hospitals nationwide [5]

上海盟科药业股份有限公司 2025 年第三次临时股东大会会议资料 证券代码：688373 证券简称：盟科药业 上海盟科药业股份有限公司 2025 年第三次临时股东大会 会议资料 二 O 二五年十一月 | 年第三次临时股东大会会议须知 2 2025 | | | --- | --- | | 2025 年第三次临时股东大会会议议程 4 | | | 议案一 | 6 | | 关于取消监事会并修订《公司章程》的议案 | 6 | | 议案二 | 7 | | 关于修订部分公司治理制度的议案 7 | | | 议案三 | 8 | | 关于聘请公司 年度审计机构的议案 8 2025 | | | 议案四 | 9 | | 关于部分募集资金投资项目变更的议案 9 | | | 议案五 | 15 | | 关于购买董事及高管责任险的议案 15 | | 上海盟科药业股份有限公司 2025 年第三次临时股东大会会议资料 上海盟科药业股份有限公司 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》 ...

10月27日晚间，盟科药业-U（688373.SH）披露2025年三季报。前三季度，公司营业收入实现1.04亿 元，同比小幅增长6.58%，归属母公司股东的净亏损1.94亿元，同比收窄33.56%。三季报数据显示，截 至9月末，公司货币资金及交易性金融资产合计4.84亿元，较2024年末有所下降。财务数据表现虽不亮 眼，但眼观未来，盟科药业目前或处于业务经营从低谷回暖的关键时刻。 作为一家生物科技公司，盟科药业目前主要收入来源于首个商业化产品康替唑胺片。据了解，该产品是 公司自主设计和开发的新一代噁唑烷酮类抗菌药，可用于治疗复杂性皮肤和软组织感染等。光大证券指 出，一些临床研究证实，康替唑胺片体现出相较目前主流"超级抗生素"利奈唑胺更出色的安全性和疗效 稳定性，能克服噁唑烷酮类药物临床应用中骨髓抑制的痛点，临床价值突出。然而自2021年上市以来， 康替唑胺片放量速度并不亮眼，商业化兑现能力成为公司短板。 不仅如此，公司在研注射用多黏菌素类药物MRX-8的中美Ⅰ期临床试验均已顺利完成，已获FDA孤儿 药认证的新型苯并硼唑类抗生素MRX-5在澳大利亚的Ⅰ期临床试验也已完成。 此外，围绕ADC领域，公司指出，基于团 ...

Core Insights - Amgen Pharmaceuticals (688373.SH) reported a total operating revenue of 104 million yuan for the first three quarters of 2025, representing a year-on-year increase of 6.58% [1] - The net profit attributable to shareholders of the parent company was -194 million yuan, which is a reduction in losses by 97.76 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.3 yuan [1]

Core Viewpoint - Mengke Pharmaceutical (SH 688373) reported a revenue of approximately 104 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.58%. However, the company recorded a net loss attributable to shareholders of approximately 194 million yuan [1][1][1]. Company Summary - Mengke Pharmaceutical's revenue for the first three quarters of 2025 is about 104 million yuan, which is a 6.58% increase compared to the same period last year [1][1][1]. - The net profit attributable to shareholders for the same period is a loss of approximately 194 million yuan [1][1][1]. - As of the report date, Mengke Pharmaceutical has a market capitalization of 5 billion yuan [1][1][1].

Financial Performance - The company's operating revenue for the third quarter was ¥37,015,530.15, representing a year-on-year increase of 0.52%[4] - The total profit for the quarter was a loss of ¥54,848,430.68, with a cumulative loss of ¥193,407,150.71 for the year-to-date[4] - The net profit attributable to shareholders for the quarter was a loss of ¥54,861,654.71, with a year-to-date loss of ¥193,536,147.26[4] - Total operating revenue for the first three quarters of 2025 reached ¥103,985,283.24, an increase of 6.9% compared to ¥97,562,309.83 in the same period of 2024[20] - Net loss for the first three quarters of 2025 was ¥193,536,147.26, compared to a net loss of ¥291,296,145.99 in the same period of 2024, indicating an improvement of 33.6%[21] - The basic and diluted earnings per share for the quarter were both -¥0.08[5] - The basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.30, an improvement from -¥0.44 in the same period of 2024[21] Research and Development - Research and development expenses totaled ¥56,333,880.25 for the quarter, a decrease of 27.85% compared to the previous year[5] - The ratio of R&D expenses to operating revenue was 152.19%, down 59.84 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2025 were ¥172,747,166.04, down from ¥244,246,074.92 in 2024, a decrease of 29.3%[20] Assets and Liabilities - Total assets at the end of the quarter were ¥726,934,188.94, a decrease of 14.39% from the end of the previous year[5] - Total current assets decreased from 748,661,957.20 RMB to 640,046,361.72 RMB, a decline of approximately 14.5%[15] - Total liabilities increased from 335,037,523.23 RMB to 400,211,748.73 RMB, an increase of approximately 19.5%[16] - The company reported a total of ¥2,366,460.10 in non-recurring gains and losses for the quarter[8] - The company's total liabilities increased to ¥469,380,110.62 from ¥410,164,907.91, an increase of 14.4%[20] - Total assets decreased from 849,128,659.62 RMB to 726,934,188.94 RMB, a decrease of about 14.4%[16] Cash Flow - Cash flow from operating activities showed a net outflow of ¥165,628,026.86, an improvement from a net outflow of ¥293,485,930.62 in the previous year[24] - Cash inflow from investment activities totaled ¥1,930,610,524.90, compared to ¥1,904,622,936.40 in the same period of 2024, reflecting a slight increase[24] - Cash inflow from financing activities was $91,702,238.69, down from $100,000,000.00, while cash outflow for financing activities increased to $37,650,658.55 from $26,070,254.51, resulting in a net cash flow from financing activities of $54,051,580.14, down from $73,929,745.49[25] - The net increase in cash and cash equivalents was $63,700,257.64, compared to $116,538,132.46 in the previous period, with an ending cash balance of $337,032,548.26, up from $254,014,785.61[25] - The impact of exchange rate changes on cash and cash equivalents was a decrease of $1,608,325.68, an improvement from a decrease of $3,394,068.68 in the prior period[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,492[12] - Genie Pharma holds 10.92% of shares, totaling 71,572,817 shares[12] - The company has no significant changes in the top ten shareholders or their shareholding status[13]

Core Insights - The company reported third-quarter revenue of 37.02 million yuan, representing a year-on-year increase of 0.52% [1] - The net profit for the third quarter showed a loss of 54.86 million yuan [1] - For the first three quarters, the company achieved revenue of 104 million yuan, reflecting a year-on-year growth of 6.58% [1] - The net profit for the first three quarters resulted in a loss of 194 million yuan [1]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025年第三次临时股东大会 网络投票系统：上海证券交易所股东大会网络投票系统 证券代码：688373 证券简称：盟科药业 公告编号：2025-059 网络投票起止时间：自2025年11月7日 上海盟科药业股份有限公司 至2025年11月7日 关于召开2025年第三次临时股东大会的通知 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 （四）现场会议召开的日期、时间和地点 召开日期时间：2025年11月7日 14点00分 召开地点：中国（上海）自由贸易试验区爱迪生路53号 （五）网络投票的系统、起止日期和投票时间。 ■ 1、说明各议案已披露的时间和披露媒体 （六）融资融券 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-059 上海盟科药业股份有限公司 关于召开2025年第三次临时股东大会的通知 （一） 股东大会类型和届次 2025年第三次临时股东大会 召开日期时间：2025 年 11 月 7 日 14 点 00 分 召开地点：中国（上海）自由贸易试验区爱迪生路 53 号 （五） 网络投票的系统、起止日期和投票时间。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 7 日 至2025 年 11 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 股东大会召开日期：2025年11月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大 ...

Governance Crisis - The major shareholder, Genie Pharma, opposed the proposed private placement and called for the removal of the founder and chairman, Yuan Zhengyu, along with two other directors, proposing three new directors from BVCF [1] - Concerns were raised regarding the financial strength and integration capabilities of the private placement target, Nanjing Haijing Pharmaceutical, which has total assets of approximately 700 million [1] - Independent director Zhao Yachao cast the only dissenting vote against the private placement, indicating a lack of trust in the current management team [1] Operational Challenges - The company focuses on the development of small molecule drugs for anti-infection, with its only commercial product being the lanzoprazole tablet launched in 2021 [2] - The product faces competition from major players like Pfizer and Merck, leading to weak market performance [2] - Financial data shows the company has been in a long-term loss state, with cumulative losses of approximately 1.22 billion from 2022 to the first half of 2025, and revenue growth slowing from over 40% in 2024 to 10.26% [2] Financial Pressure - The company reduced R&D investment by 30% year-on-year to 116 million in the first half of 2025, citing strict cost control, reflecting a tight cash flow situation [3] - As of the end of the first half of 2025, the company had only 237 million in cash, with negative cash flow from operating activities totaling over 1.1 billion since 2022 [3] - The company's net assets have decreased by 74.19% since its IPO, and the debt-to-asset ratio has surged from 18.91% to 59.45% over three years [3] Market Confidence Erosion - Following the lifting of the lock-up period for initial public offering shares in August 2025, several shareholders, including MicuRx and Best Idea, announced plans to reduce their holdings, causing panic in the secondary market [4] - On September 10, the company's stock price fell by 7.03% in a single day, with investors expressing pessimism about the company's future [4] Conclusion - The private placement dispute reflects deeper issues related to governance, strategic direction, and shareholder trust [5] - The ability to successfully attract strategic investors, balance interests, and rebuild market confidence will determine whether the company can escape the cycle of losses and financing [5]